Abstract Objective To study the clinical features of children with adenovirus pneumonia and hemophagocytic lymphohistiocytosis (HLH). Methods A retrospective analysis was performed on the mediacal data of 7 children with adenovirus pneumonia and HLH from March to September, 2019. Results The age of these children ranged from 11 months to 5 years, and among these children, 5 were aged < 2 years and 5 were boys. None of these children had underlying diseases. All children were hospitalized due to persistent high fever and cough, and the peak temperature of fever was 39℃ to 41℃. With disease progression, 7 children developed hepatomegaly and 6 developed splenomegaly. Routine blood test results showed reductions in two or three lineages of blood cells, with increases in serum ferritin (SF), C-reactive protein (CRP), procalcitonin (PCT), and lactate dehydrogenase (LDH). Phagocytosis of blood cells was observed in 6 children. Radiological examination of lungs showed pneumonia changes. All 7 children were diagnosed with human adenovirus type 7 infection based on pathogenic metagenome detection. No abnormality was found by HLH gene detection and the children were diagnosed with secondary HLH. All children received intravenous immunoglobulin. Among these children, 4 received dexamethasone and etoposide chemotherapy, 3 received dexamethasone alone, and 4 received plasma exchange. Of the 7 children, 2 died and 5 were recovered. Compared with those who survived, the children who died had significantly greater reductions in the three lineages of blood cells and significantly greater increases in serum levels of CRP, PCT, SF, and LDH. Conclusions The children with adenovirus pneumonia and HLH have main clinical features of persistent high fever, progressive reductions in two or three lineages of peripheral blood cells, and involvement of other organ systems, including hepatosplenomegaly. Significant increases in serum levels of CRP, PCT, SF, and LDH may suggest a poor prognosis.
CHEN Jie,CHEN Xi,TAN Xin-Rui et al. Adenovirus pneumonia with hemophagocytic lymphohistiocytosis in children: a clinical analysis of 7 children[J]. CJCP, 2020, 22(7): 749-754.
CHEN Jie,CHEN Xi,TAN Xin-Rui et al. Adenovirus pneumonia with hemophagocytic lymphohistiocytosis in children: a clinical analysis of 7 children[J]. CJCP, 2020, 22(7): 749-754.
Mellon G, Henry B, Aoun O, et al. Adenovirus related lymphohistiocytic hemophagocytosis:case report and literature review[J]. J Clin Virol, 2016, 78:53-56.
[4]
Censoplano N, Gorga S, Waldeck K, et al. Neonatal adenovirus infection complicated by hemophagocytic lymphohistiocytosis syndrome[J]. Pediatrics, 2018, 141(Suppl 5):S475-S480.
Henter JI, Horne A, Aricó M, et al. HLH-2004:diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2):124-131.
[7]
Maakaroun NR, Moanna A, Jacob JT, et al. Viral infections associated with haemophagocytic syndrome[J]. Rev Med Virol, 2010, 20(2):93-105.
[8]
Lachmann G, La Rosée P, Schenk T, et al. Hemophagocytic lymphohistiocytosis:a diagnostic challenge on the ICU[J]. Anaesthesist, 2016, 65(10):776-786.
[9]
Machowicz R, Janka G, Wiktor-Jedrzejczak W. Similar but not the same:differential diagnosis of HLH and sepsis[J]. Crit Rev Oncol Hematol, 2017, 114:1-12.
[10]
Simon DW, Halstead ES, Davila S, et al. DNA viremia is associated with hyperferritinemia in pediatric sepsis[J]. J Pediatr, 2019, 213:82-87.e2.
Ampuero JS, Ocaña V, Gómez J, et al. Adenovirus respiratory tract infections in Peru[J]. PLoS One, 2012, 7(10):e46898.
[13]
Hiwarkar P, Amrolia P, Sivaprakasam P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant[J]. Blood, 2017, 129(14):2033-2037.
[14]
Ronchi A, Doern C, Brock E, et al. Neonatal adenoviral infection:a seventeen year experience and review of the literature[J]. J Pediatr, 2014, 164(3):529-535.e354.
[15]
Demirkol D, Yildizdas D, Bayrakci B, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome:what is the treatment?[J]. Crit Care, 2012, 16(2):R52.
